Merck KGaA has enjoyed a solid share price climb over the past year, which puts a spotlight on whether that move is matched by what the business is earning. With fresh deal activity and partnerships in the background, the live question for investors is how well today's valuation lines up with its earnings power.

• The stock has returned 30.1% over the past year, which makes it important to test whether that gain is grounded in its earnings rather than just sentiment.

• The planned US$1.3b purchase of Silence Therapeutics, focused on rare disease treatments, can reshape expected profitability and cash needs as Merck KGaA folds a new late stage asset into its pipeline.

• There is a second opinion on Merck KGaA worth weighing. See what analysts think Merck KGaA's shares could be worth .

The issue now is whether Merck KGaA's current share price is adequately supported by its earnings when set against the Fair Ratio benchmark.

If you want to test the same question you are asking of Merck KGaA's earnings against a wider field of potential ideas, start with 193 high quality undervalued stocks .

Is Merck KGaA Fairly Priced on Earnings?

P/E fits Merck KGaA because earnings still anchor most of the debate around its value. The stock trades on a P/E of 26.9x, compared with about 21.2x for the wider Pharmaceuticals sector and a peer group closer to 46.5x. That leaves Merck KGaA priced above the broad industry but below more highly rated rivals, which already indicates the market is assigning it a premium to the average drug maker without placing it in the most expensive tier.

The Fair Ratio model, which blends factors like growth expectations, margins, size and risk into a tailored benchmark, suggests Merck KGaA's current P/E multiple is broadly in line with what those fundamentals support. Because the planned US$1.3b Silence Therapeutics deal sharpens the focus on future earnings and cash needs, the fact that the market price does not extend far beyond this Fair Ratio points to a valuation that is not obviously aggressive or distressed on this metric. Explore the numbers behind Merck KGaA's P/E valuation .

The Merck KGaA Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Merck KGaA valuation puzzle leaves off and spell out which paths for growth, profitability and earnings would need to play out for the stock to be worth meaningfully more or less than today's level, based on the assumptions used by different community members.

Each scenario focuses less on a single multiple or model number and more on the inputs behind its view of fair worth, so you can later compare those expectations with Merck KGaA's actual results as they are reported.